Imagine trying to grow a delicate plant in soil that might have hidden weeds; sometimes the weeds ruin the whole garden. Most vaccine eggs have bacteria inside the shell that can't be washed away, often ruining entire batches of medicine. This project creates a way to produce eggs that are completely germ-free from the start. It's like moving from a dusty backyard to a sterile laboratory for the eggs themselves.
Up to 30% of high-grade vaccine eggs contain internal bacteria that cannot be removed, leading to ruined vaccine batches and a 4-week delay in quality confirmation.
A mass-production process for 100% bacteria-free eggs suitable for vaccines including Influenza, COVID-19, and Yellow Fever.
If you are a vaccine manufacturer dealing with batch rejections due to internal egg contamination—this project developed germ-free eggs that eliminate the 30% internal bacteria rate. This prevents the loss of expensive vaccine batches and reduces delays to market.
If you are a biopharmaceutical producer dealing with a 4-week lag time for microbiological monitoring—this project developed a superior germ-free product. This removes the risk of using infected eggs that lead to production failures.
If you are an SPF egg producer dealing with global shortages of high-grade eggs—this project developed a method for mass production of 100% bacteria-free eggs. This allows you to capture the high-demand market for pandemic-ready vaccine infrastructure.
Based on available project data, specific pricing or cost per unit is not provided.
Yes, the objective is to bring the world's first Germ Free egg into mass production and accelerate international scale-up to increase global manufacturing capacity.
Based on available project data, specific licensing terms are not mentioned, but the technology is developed by Ovagen Group Limited.
It eliminates the 4-week lag time required to confirm infection in SPF eggs, which currently causes delays to market and patient vaccinations.
It fits into traditional vaccine production infrastructure, which is already well established for viruses like influenza and yellow fever.
The project is led by a single SME, Ovagen Group Limited, based in Ireland. With a 100% industry ratio and no university or research partners, the focus is purely on commercial execution and scaling rather than basic research.
Contact Ovagen Group Limited in Ireland
Contact us to find similar bio-manufacturing scale-up opportunities.
